Pharmacogenetics of the PPAR genes and cardiovascular disease

Pharmacogenomics

Volumn 8, Issue 11, 2007, Pages 1581-1595

  Cresci, Sharon ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac disease; Cardiovascular disease; Pharmacogenetics; Pharmacogenomics; Polymorphism; PPAR; Single nucleotide polymorphism

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADIPOCYTOKINE; ANTILIPEMIC AGENT; BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLIMEPIRIDE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; METFORMIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; POLYPEPTIDE; PRAVASTATIN; RAGAGLITAZAR; ROSIGLITAZONE; SULFONYLUREA; TESAGLITAZAR; TROGLITAZONE; UNINDEXED DRUG;

ANEMIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CREATININE BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; ENERGY BALANCE; GENE FUNCTION; GENETIC REGULATION; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; GLUCOSE HOMEOSTASIS; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LEUKOPENIA; LIVER TOXICITY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIPHERAL EDEMA; PHARMACOGENETICS; PLEIOTROPY; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIDE EFFECT; STROKE; SUDDEN DEATH; WEIGHT GAIN;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; LIGANDS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHARMACOGENETICS; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 37349124557     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.11.1581     Document Type: Review

References (144)

1. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W: Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68, 879-887 (1992).
2. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137, 354-366 (1996).
3. Chew CH, Samian MR, Najimudin N, Tengku-Muhammad TS: Molecular characterisation of six alternatively spliced variants and a novel promoter in human peroxisome proliferator-activated receptor α. Biochem. Biophys. Res. Commun. 305, 235-243 (2003).
4. Fajas L, Auboeuf D, Raspe E et al.: The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem. 272, 18779-18789 (1997).
5. Fredenrich A, Grimaldi PA: PPAR δ: an uncompletely known nuclear receptor. Diabetes Metab. 31, 23-27 (2005).
6. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP: Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth. J. Clin. Invest. 105, 1723-1730 (2000).
7. Djouadi F, Weinheimer CJ, Saffitz JE et al.: A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α-deficient mice. J. Clin. Invest. 102, 1083-1091 (1998).
8. Finck BN, Han X, Courtois M et al.: A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl Acad. Sci. USA 100, 1226-1231 (2003).
9. Guerre-Millo M, Rouault C, Poulain P et al.: PPAR-α-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 50, 2809-2814 (2001).
10. 2-dependent modulation of mitochondrial fatty acid oxidation. J. Biol. Chem. 276, 27605-27612 (2001).
11. Huss JM, Kelly DP: Nuclear receptor signaling and cardiac energetics. Circ. Res. 95, 568-578 (2004).
12. Huss JM, Kelly DP: Mitochondrial energy metabolism in heart failure: a question of balance. J. Clin. Invest. 115, 547-555 (2005).
13. Lemberger T, Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu. Rev. Cell Dev. Biol. 12. 335-363 (1996).
14. Lemberger T, Saladin R, Vazquez M et al.: Expression of the peroxisome profiferator-activated receptor α gene is stimulated by stress and follows a diurnal rhythm. J. Biol. Chem. 271, 1764-1769 (1996).
15. Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferator-activated receptor a (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 96, 7473-7478 (1999).
16. Cresci S, Wright LD, Spratt JA, Briggs FN, Kelly DP: Activation of a novel metabolic gene regulatory pathway by chronic stimulation of skeletal muscle. Am. J. Physiol. 270, C1413-C1420 (1996).
17. Inoue I, Shino, K, Noji S, Awata T, Katayama S: Expression of peroxisome proliferator-activated receptor a (PPARα) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun. 246, 370-374 (1998).
18. Staels B, Koenig W, Habib A et al.: Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARα activators. Nature 393, 790-793 (1998).
19. Jones DC, Ding X, Daynes RA: Nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is expressed in resting murine lymphocytes. The PPARα in T and B lymphocytes is both transactivation and transrepression competent. J. Biol. Chem. 277, 6838-6845 (2002).
20. Zhu Y, Alvares K, Huang Q, Rao MS, Reddy JK: Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J. Biol. Chem. 268, 26817-26820 (1993).
21. Imai T, Takakuwa R, Marchand S et al.: Peroxisome proliferator-activated receptor γ is required in mature white and brown adipocytes for their survival in the mouse. Proc. Natl Acad. Sci. USA 101, 4543-4547 (2004).
22. Rosen ED, Sarraf P, Troy AE et al.: PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4, 611-617 (1999).
23. Spiegelman BM: Peroxisome proliferator-activated receptor γ: a key regulator of adipogenesis and systemic insulin sensitivity. Eur. J. Med. Res. 2, 457-464 (1997).
24. Miles PD, Barak Y, He W, Evans RM, Olefsky JM: Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest. 105, 287-292 (2000).
25. Ahima RS, Flier JS: Adipose tissue as an endocrine organ. Trends Endocrinal. Metab. 11, 327-332 (2000).
26. Amri EZ, Bonino F, Ailhaud G, Abumrad NA, Grimaldi PA: Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. J. Biol. Chem. 270, 2367-2371 (1995).
27. Peters JM, Lee SS, Li W et al.: Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol. Cell Biol. 20, 5119-5128 (2000).
28. Matsusue K, Peters JM, Gonzalez FJ: PPARβ/δ potentiates PPARγ-stimulated adipocyte differentiation. FASEB. J. 18, 1477-1479 (2004).
29. Tanaka T, Yamamoto J, Iwasaki S et al.: Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl Acad. Sci. USA 100, 15924-15929 (2003).
30. Gilde AJ, van der Lee KA, Willemsen PH et al.: Peroxisome proliferator-activated receptor (PPAR) α and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res. 92, 518-524 (2003).
31. Cheng L, Ding G, Qin Q et al.: Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10, 1245-1250 (2004).
32. Planavila A, Laguna JC, Vazquez-Carrera M: Nuclear factor-κB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J. Biol. Chem. 280, 17464-17471 (2005).
33. Planavila A, Rodriguez-Calvo R, Jove M et al.: Peroxisome proliferator-activated receptor β/δ activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc. Res. 65, 832-841 (2005).
34. Barish GD, Narkar VA, Evans RM: PPAR δ: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116, 590-597 (2006).
35. Berkenstam A, Gustafsson JA: Nuclear receptors and their relevance to diseases related to lipid metabolism. Curr. Opin. Pharmacol. 5, 171-176 (2005).
36. Benoit G, Malewicz M, Perlmann T: Digging deep into the pockets of orphan nuclear receptors: insights from structural studies. Trends Cell Biol. 14, 369-376 (2004).
37. Nolte RT, Wisely GB, Westin S et al.: Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395, 137-143 (1998).
38. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358, 771-774 (1992).
39. Qi C, Zhu Y, Reddy JK: Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem. Biophys. 32, 187-204 (2000).
40. Zhu Y, Kan L, Qi C et al.: Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J. Biol. Chem. 275, 13510-13516 (2000).
41. Spiegelman BM, Puigserver P, Wu Z: Regulation of adipogenesis and energy balance by PPARγ and PGC-1. Int. J. Obes. Relat. Metab. Disord. 24(Suppl. 4), S8-S10 (2000).
42. Luquet S, Lopez-Soriano J, Holst D et al.: Roles of peroxisome proliferator-activated receptor δ (PPARδ) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie 86, 833-837 (2004).
43. Yang Q, Li Y: Roles of PPARs on regulating myocardial energy and lipid homeostasis. J. Mol. Med. 85, 697-706 (2007).
44. Flavell DM, Pineda Torra I, Jamshidi Y et al.: Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia 43, 673-680 (2000).
45. Tai ES, Corella D, Demissie S et al.: Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J. Nutr. 135, 397-403 (2005).
46. Chuang LM, Hsiung CA, Chen YD et al.: Sibling-based association study of the PPARγ2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. Stanford Asian-Pacific Program in Hypertension and Insulin Resistance. J Mol. Med. 79, 656-664 (2001).
47. Andrulionyte L, Zacharova J, Chiasson JL, Laakso M: Common polymorphisms of the PPAR-γ2 (Pro12Ala) and PGC-1α (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to Type 2 diabetes in the STOPNIDDM trial. Diabetologia 47, 2176-2184 (2004).
48. Ek J, Andersen G, Urhammer SA et al.: Mutation analysis of peroxisome proliferator-activated receptor-γ coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia 44, 2220-2226 (2001).
49. Ostergard T, Ek J, Hamid Y et al.: Influence of the PPAR-γ2 Pro12Ala and ACE I/D polymorphisms on insulin sensitivity and training effects in healthy offspring of Type 2 diabetic subjects. Horm. Metab. Res. 37, 99-105 (2005).
50. Shin HD, Park BL, Kim LH et al.: Genetic polymorphisms in peroxisome proliferator-activated receptor δ associated with obesity. Diabetes 53, 847-851 (2004).
51. Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P. Ehrenborg E: Evidence that peroxisome proliferator-activated receptor δ influences cholesterol metabolism in men. Arterioscler. Thromb. Vasc. Biol. 23, 637-643 (2003).
52. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR: Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med. 339, 953-959 (1998).
53. Nemoto M, Sasaki T, Deeb SS, Fujimoto WY, Tajima N: Differential effect of PPARγ2 variants in the development of Type 2 diabetes between native Japanese and Japanese Americans. Diabetes Res. Clin. Pract. 57, 131-137 (2002).
54. Gonzalez Sanchez JL, Serrano RM, Fernandez PC, Laakso M, Martinez Larrad MT: Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur. J. Endocrinol. 147, 495-501 (2002).
55. Meirhaeghe A, Fajas L, Gouilleux F et al.: A functional polymorphism in a STAT5B site of the human PPARγ 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler. Thromb. Vasc. Biol. 23, 289-294 (2003).
56. Cresci S: The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics. Expert Opin. Pharmacother. 6, 2577-2591 (2005).
57. Sapone A, Peters JM, Sakai S et al.: The human peroxisome proliferator-activated receptor α gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics 10, 321-333 (2000).
58. Vohl MC, Lepage P, Gaudet D et al.: Molecular scanning of the human PPARα gene: association of the L162v mutation with hyperapobetalipoproteinemia. J. Lipid Res. 41, 945-952 (2000).
59. Tai ES, Demissie S, Cupples LA et al.: Association between the PPARA L162V. polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 22, 805-810 (2002).
60. Flavell DM, Jamshidi Y, Hawe E et al.: Peroxisome proliferator-activated receptor α gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 105, 1440-1445 (2002).
61. Jamshidi Y, Montgomery HE, Hense HW et al.: Peroxisome proliferator - activated receptor α gene regulates left ventricular growth in response to exercise and hypertension. Circulation 105, 950-955 (2002).
62. Deeb SS, Fajas L, Nemoto M et al.: A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20, 284-287 (1998).
63. Doney AS, Fischer B, Leese G, Morris AD, Palmer CN: Cardiovascular risk in Type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler. Thromb. Vasc. Biol. 24, 2403-2407 (2004).
64. Ridker PM, Cook NR, Cheng S et al.: Alanine for proline substitution in the peroxisome proliferator-activated receptor γ-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 23, 859-863 (2003).
65. Iwata E, Yamamoto I, Motomura T et al.: The association of Pro12Ala polymorphism in PPARγ2 with lower carotid artery IMT in Japanese. Diabetes Res. Clin. Pract. 62, 55-59 (2003).
66. Al-Shali KZ, House AA, Hanley AJ et al.: Genetic variation in PPARG encoding peroxisome proliferator-activated receptor γ associated with carotid atherosclerosis. Stroke 35, 2036-2040 (2004).
67. Skogsberg J, McMahon AD, Karpe F, Hamsten A, Packard CJ, Ehrenborg E: Peroxisome proliferator activated receptor δ genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J. Intern. Med. 254, 597-604 (2003).
68. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650 (1990).
69. Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl Acad. Sci. USA 94, 4312-4317 (1997).
70. Kliewer SA, Sundseth SS, Jones SA et al.: Fatty acids and elcosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl Acad. Sci. USA 94, 4318-4323 (1997).
71. Kesaniemi YA, Grundy SM: Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA 251, 2241-2246 (1984).
72. Elisaf M: Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18, 269-276 (2002).
73. The FIELD Study Investigators: The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ISRCTN64783481. Cardiovasc. Diabetol. 3,9 (2004).
74. Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
75. Peters JM, Aoyama T, Burns AM, Gonzalez FJ: Bezafibrate is a dual ligand for PPARα and PPARβ: studies using null mice. Biochim. Biophys. Acta 1632, 80-89 (2003).
76. Ericsson C G, Nilsson J, Grip L, Svane B, Hamsten A: Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am. J. Cardiol. 80, 1125-1129 (1997).
77. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angtographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347, 849-853 (1996).
78. Frick MH, Syvanne M, Nieminen MS et al.: Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 2137-2143 (1997).
79. 2-cholesterol response of abdominally obese men treated with gemfibrozil. Genet. Med. 4, 311-315 (2002).
80. Frick MH, Elo O, Haapa K et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237-1245 (1987).
81. Manninen V, Tenkanen L, Koskinen P et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85, 37-45 (1992).
82. Tenkanen L, Manttari M, Manninen V: Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Cirrulation 92, 1779-1785 (1995).
83. Tai ES, Collins D, Robins SJ et al.: The L162V polymorphism at the peroxisome proliferator activated receptor a locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 187, 153-160 (2006).
84. Robins SJ, Collins D, Wittes JT et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285, 1585-1591 (2001).
85. Rubins HB, Robins SJ, Collins D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410-418 (1999).
86. Bloomfield RH, Davenport J, Babikian V et al.: Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 103, 2828-2833 (2001).
87. Robins SJ, Rubins HB, Faas FH et al.: Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 26, 1513-1517 (2003).
88. Rubins HB, Robins SJ, Collins D et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein Intervention trial (VA-HIT). Arch. Intern. Med. 162, 2597-2604 (2002).
89. Steiner G, Stewart D, Hosking JD: Baseline characteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS). World Health Organization Collaborating Centre for the Study of Atherosclerosis in Diabetes. Am. J. Cardiol. 84, 1004-1010 (1999).
90. Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet 357, 905-910 (2001).
91. Ansquer JC, Foucher C, Rattler S, Taskinen MR, Steiner G: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in Type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J. Kidney Dis. 45, 485-493 (2005).
92. Foucher C, Rattler S, Flavell DM et al.: Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors α G/C intron7 polymorphism in subjects with Type 2 diabetes. Pharmacogenetics 14, 823-829 (2004).
93. Auwerx J: PPARγ, the ultimate thrifty gene. Diabetologia 42, 1033-1049 (1999).
94. Otto C, Lehrke M, Goke B: Novel insulin sensitizers: pharmacogenomic aspects. Pharmacogenomics 3, 99-116 (2002).
95. Ghazzi MN, Perez JE, Antonucci TK et al.: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46, 433-439 (1997).
96. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW: Troglitazone monotherapy improves glycemic control in patients with Type 2 diabetes meltitus: a randomized, controlled study. The Troglitazone Study Group. J. Clin. Endocrinol. Metab. 83, 3169-3176 (1998).
97. Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL: The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with Type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 134, 737-745 (2001).
98. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW: Troglitazone in combination with sulfonylurea restores glycemic control in patients with Type 2 diabetes. The Troglitazone Study Group. Diabetes Care 21, 1462-1469 (1998).
99. Kumar S, Boulton AJ, Beck-Nielsen H et al.: Troglitazone, an Insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia 39, 701-709 (1996).
100. Sakamoto J, Kimura H, Moriyama S et al.: Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun. 278, 704-711 (2000).
101. Yki-Jarvinen H: Thiazolidinediones. N. Engl. J. Med. 351, 1106-1118 (2004).
102. Khan MA, St PJ, Xue JL: A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with Type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25, 708-711 (2002).
103. Tang WH, Maroo, A: PPARγ agonists: safety issues in heart failure. Diabetes Obes. Metab. 9, 447-454 (2007).
104. Patel C, Wyne KL, McGuire DK: Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab. Vasc. Dis. Res. 2, 61-66 (2005).
105. Nesto RW, Bell D, Bonow RO et al.: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108, 2941-2948 (2003).
106. Pfutzner A, Marx N, Lubben G et al.: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J. Am. Coll. Cardiol. 45, 1925-1931 (2005).
107. Satoh N, Ogawa Y, Usui T et al.: Antiatherogenic effect of pioglitazone in Type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26, 2493-2499 (2003).
108. Langenfeld MR, Forst T, Hohberg C et al.: Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with Type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111, 2525-2531 (2005).
109. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A: The Prospective Pioglitazone Clinical Trial In Macrovascular Events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 27, 1647-1653 (2004).
110. Dormandy JA, Charbonnel B, Eckland DJ et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial In Macrovascular Events): a randomised controlled trial. Lancet 366, 1279-1289 (2005).
111. Wilcox R, B6usser MG, Betteridge DJ et al.: Effects of pioglitazone in patients with Type 2 diabetes with or without previous stroke: results from PROactive (Prospective PioglitAzone Clinical Trial In Macrovascular Events 04). Stroke 38, 865-873 (2007).
112. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with Type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J. Am. Coll. Cardiol. 49, 1772-1780 (2007).
113. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007).
114. Psaty BM, Furberg CD: Rosiglitazone and cardiovascular risk. N. Engl. J. Med. 356, 2522-2524 (2007).
115. Kang ES, Park SY, Kim HJ et al.: Effects of Pro12A1a polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in Type 2 diabetes. Clin. Pharmacol. Ther. 78, 202-208 (2005).
116. Jaziri R, Lobberis S, Aubert R et al.: The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) study. Diabetes 55, 1157-1162 (2006).
117. Wolford JK, Yeatts KA, Dhanjal SK et al.: Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 54, 3319-3325 (2005).
118. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA: TRIPOD (Troglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin. Trials 19, 217-231 (1998).
119. Buchanan TA, Xiang AH, Peters RK et al.: Preservation of pancreatic β-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51, 2796-2803 (2002).
120. Snitker S, Watanabe RM, Ani I et al.: Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-γ2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 27, 1365-1368 (2004).
121. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
122. Colhoun HM, Betteridge DJ, Durrington PN et al.: Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetalogia 48, 2482-2485 (2005).
123. Colhoun HM, Betteridge DJ, Durrington PN et al.: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685-696 (2004).
124. LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435 (2005).
125. Shepherd J, Barter P, Carmena R et al.: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29, 1220-1226 (2006).
126. Waters DD, LaRosa JC, Barter P et al.: Effects of high-close atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J. Am. Coll. Cardiol. 48, 1793-1799 (2006).
127. Steiner G: A new perspective in the treatment of dyslipidemia: can fenofibrate offer unique benefits in the treatment of Type 2 diabetes mellitus? Treat. Endocrinol. 4, 311-317 (2005).
128. Steiner G: Lipid intervention trials in diabetes. Diabetes Care 23(Suppl. 2), B49-B53 (2000).
129. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S: Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol. Res. 45, 147-154 (2002).
130. Inoue I, Goto S, Mizotani K et al.: Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci. 67, 863-876 (2000).
131. Chen S, Tsybouleva N, Ballantyne CM, Gotto AM Jr, Marian AJ: Effects of PPARα, γ and δ haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 14, 61-71 (2004).
132. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M: The STOP-NIDDM Trial: an international study on the efficacy of an α-glucosidase inhibitor to prevent Type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 21, 1720-1725 (1998).
133. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of Type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet359, 2072-2077 (2002).
134. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290, 486-494 (2003).
135. Andrulionyte L, Peltola, P, Chiasson JL, Laakso M: Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to Type 2 diabetes: the STOP-NIDDM trial. Diabetes 5 5, 2148-2152 (2006).
136. Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M: Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-α gene (PPARA) influence the conversion from impaired glucose tolerance to Type 2 diabetes: the STOP-NIDDM trial. Diabetes 56, 1181-1186 (2007).
137. Saad MF, Greco S, Osei K et al.: Ragaglitazar improves glycemic control and lipid profile in Type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care 27, 1324-1329 (2004),
138. Brand CL, Sturis J, Gotfredsen CF et al.: Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am. J. Physiol. Endocrinol. Metab. 284, E841-E854 (2003).
139. Pickavance LC, Brand CL, Wassermann K, Wilding JP: The dual PPARα/ γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br. J. Pharmacol. 144, 308-316 (2005).
140. Egerod FL, Nielsen HS, Iversen L, Thorup-I, Storgaard T, Oleksiewicz MB: Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers 10, 295-309 (2005).
141. Buse JB, Rubin CJ, Frederich R et al.: Muraglitazar, a dual (α/γ) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with Type 2 diabetes. Clin. Ther. 27, 1181-1195 (2005).
142. Kendall DM, Rubin CJ, Mohideen P et al.: Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with Type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29, 1016-1023 (2006).
143. Nissen SE, Wolski K, Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA 294, 2581-2586 (2005).
144. Hansen L, Ekstrom CT, Tabanera YP, Anant M, Wassermann K, Reinhardt RR: The Pro1 2Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-γ/α agonist-induced edema in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. 91, 3446-3450 (2006).